https://www.psychiatrist.com/esketamine-ciii-nasal-spray-treatment-resistant-depression/
Information from Industry June 30, 2020
SPRAVATO® (esketamine) CIII Nasal Spray: The First and Only N-Methyl D-Aspartate (NMDA) Receptor Antagonist Approved in Conjunction With an Oral Antidepressant for the Treatment of Adults With Treatment-Resistant Depression
Vol 86 • 2025 • Number 3
Read the Current Issue
Original Research
Treatment Use and Preference in a Diverse Sample of Women With Mood Disorders
Original Research
Klotho and Matrix Metalloproteinase-9 Levels and Their Association with Inhibitory Dyscontrol in Adolescents with First-Episode Major Affective Disorders
Original Research
Niacin-Induced Response in Early Psychosis
Original Research
Early Ketamine Response Reduces Suicidal Events at 3 Months
Letter to the Editor
Suicide Risk among Patients with Bipolar Disorder: Sleep Disruption versus Benzodiazepine Use
Original Research
Effect of Nature Videos on the Burden of Caregivers of Patients with Dementia
Related Articles
Information from Industry
Auvelity: A Rapid-Acting Antidepressant With Multimodal Activity
September 27, 2024
AUVELITY is an FDA-approved treatment for adults with MDD. Auvelity, is a rapid-acting antidepressant with a multimodal mechanism, targeting both glutamatergic and monoaminergic pathways. Learn more about how AUVELITY...
